BioSpace News Archive

REDWOOD CITY, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) has initiated the ECLIPSE trial, a 10,000-patient registrational study to evaluate the performance of its LUNAR-2 blood test to detect colorectal cancer (CRC) in average-risk adults. The test is intended to improve CRC screening rates by offering a simpler blood test that overcomes barriers associated with current testing methods. The U.S. Preventive Services Task Force recommends screening average-ris

Q3 revenues up 20.2% year-over-year to a record $607.3 million

TRC Capital’s unsolicited “mini-tender” offer price of $192.00 per share is approximately 4.38% below the $200.80 per share closing price of Amgen’s common stock on Oct. 11, 2019, the last trading day prior to the commencement of the offer

Vanda Pharmaceuticals Inc. announced results of a comparative genomics study presented at the 2019 American Society of Human Genetics conference on October 19, 2019, entitled “Using Patterns in Regions of Homozygosity to Evaluate the Use of Dogs as Preclinical Models in Human Drug Development”..

Sales of $29.1mm, +20% (+13% organic) vs. Q3 2018

Newly Formed Clinical-Stage Biotechnology Company to Develop Treatments for Rare Pediatric Neurodegenerative Diseases

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, reported financial results for the quarter ended September 30, 2019.

Proceeds from Non-Dilutive Financing to be Used to Achieve Near-Term Milestones

The dividend will be payable on January 2, 2020, to stockholders of record on December 2, 2019.

Acquisition enhances ICON’s ability to offer customers hybrid trial solutions and site support services